D8Y0 Stock Overview
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sandoz Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 33.20 |
| 52 Week High | CHF 35.20 |
| 52 Week Low | CHF 24.20 |
| Beta | 0 |
| 11 Month Change | 4.40% |
| 3 Month Change | 24.81% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 26.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| D8Y0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -7.0% | -0.1% |
| 1Y | n/a | -19.7% | 2.4% |
Return vs Industry: Insufficient data to determine how D8Y0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how D8Y0 performed against the German Market.
Price Volatility
| D8Y0 volatility | |
|---|---|
| D8Y0 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: D8Y0 has not had significant price volatility in the past 3 months.
Volatility Over Time: D8Y0's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 22,633 | Richard Saynor | www.sandoz.com |
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
Sandoz Group AG Fundamentals Summary
| D8Y0 fundamental statistics | |
|---|---|
| Market cap | €14.40b |
| Earnings (TTM) | €71.86m |
| Revenue (TTM) | €9.31b |
200.4x
P/E Ratio1.5x
P/S RatioIs D8Y0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D8Y0 income statement (TTM) | |
|---|---|
| Revenue | US$9.98b |
| Cost of Revenue | US$5.42b |
| Gross Profit | US$4.56b |
| Other Expenses | US$4.49b |
| Earnings | US$77.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 45.74% |
| Net Profit Margin | 0.77% |
| Debt/Equity Ratio | 49.2% |
How did D8Y0 perform over the long term?
See historical performance and comparison